Form PTO-1449
INFORMATION DISCLOSURE CITATION IN AN APPLICATION
(Use several sheets if necessary)

Docket Number (Optional)	Application Number
APBI-P05-008	10/040,430
Applicant: Crabtree et al.	
Filing Date: January 7, 2002	Group Art Unit: 1656

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CM	AA	6,171,781	1/9/01	Crabtree et al.			
	AB	6,150,099	11/21/00	Crabtree et al.			
	AC	6,096,515	8/1/00	Crabtree et al.			
	AD	5,837,840	11/17/98	Crabtree et al.			
	AE	5,656,452	8/12/97	Rao et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	Translation NO
CM	AF	WO 95/08554	3/30/95	PCT				
	AG	WO 95/02053	1/19/95	PCT				
	AH	WO 94/15964	7/21/94	PCT				
	AI	WO 93/04203	3/4/93	PCT				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages Etc.)*

CM	AJ	~~Arai et al. U. S. Application No. 08/148,061 filed 11/5/93.~~
CM	AK	~~Arai et al. U. S. Application No. 08/113,971 filed 8/30/93.~~
CM	AL	~~Arai et al. U. S. Application No. 08/099,998 filed 7/30/93.~~
CM	AM	~~Arai et al. U. S. Application No. 08/088,483 filed 7/6/93.~~
CM	AN	Banerji, S. et al. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. *Mol. Cell. Biol.* 11, 4074-4087 (1991).
	AO	Bierer, B. et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. *PNAS* 87, 9231-9235 (1990).
	AP	Clipstone, N. & Crabtree. G. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. *Ann. N. Y. Acad. Sci.* 696, 20-30 (1993).
	AQ	Clipstone, N. & Crabtree, G. Identification of calcineurin as a key signaling enzyme in lymphocyte activation. *Nature* 357, 695-697 (1992).
CM	AR	Crabtree, G. Contingent genetic regulatory events in T lymphocyte activation. *Science* 243, 355-361 (1989).

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P05-008	Application Number 10/040,430
	Applicant Crabtree et al.	
	Filing Date January 7, 2002	Group Art Unit 1656

CM	AS	Crabtree, G. Pathways of T lymphocyte activation. *Abstract of NIH Grant No. R01CA39612* (1998).
	AT	Crabtree, G. Pathways of T lymphocyte activation. *Abstract of NIH Grant No. R01CA39612* (1994).
	AU	Crabtree, G. & Clipstone, N. Signal transmission between plasma membrane and nucleus of T lymphocyte. *Ann. Rev. Biochem.* 63, 1045-1083 (1994).
	AV	Durand, D. et al. Characterization of antigen receptor response elements within the interleukin-2 enhancer. *Mol. Cell. Biol.* 8, 1715-1724 (1988).
	AW	Emmel, E. et al. Nuclear association of a T-Cell transcription factor blocked by FK-506 and cyclosporin A. *Nature* 352, 803-807 (1991).
	AX	Flanagan, W. et al. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. *Nature* 352, 803-807 (1991).
	AY	Ho, S. et al. Cloning and characterization of NF-ATc and NF-ATp: the cytoplasmic components of NF-AT. *Adv. Exp. Med. Biol.* 365, 167 (1994).
	AZ	Israel, A. NF-AT comes under control. *Nature* 369, 443-444 (1994).
	BA	Jain et al. Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. *J. Immunol.* 151, 837-848 (1993).
	BB	Jain, J. et al. Nuclear factor of activated T cells contains Fos and Jun. *Nature* 356, 801-804 (1992).
	BC	Jain et al. The T cell transcription factor NF-ATp is a substrate for calcineurin and interacts with Fos and Jun. *Nature* 365, 352-355 (1993).
	BD	Jin, Y. et al. Molecular cloning of a membrane-associated human FK-506 and rapamycin-binding protein FKBP-13. *PNAS* 88, 6677-6681 (1991).
	BE	Matilla, P. et al. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. *EMBO J.* 9, 4425-4433 (1990).
	BF	McCaffrey et al. Isolation of the cyclosporin-sensitive T cell transcription factor NF-ATp. *Science* 262, 750-754 (1993).
	BG	McCaffrey et al. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. *J. Biol. Chem.* 268, 3747-3752 (1993).
	BH	Northrop et al. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. *J. Biol. Chem.* 268, 2917-2923 (1993).
CM	BI	Northrop et al. NF-AT components define a family of transcription factors targeted in T-Cell Activation. *Nature* 369, 497-502 (1994).

COPY OF PAPERS ORIGINALLY FILED

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) APBI-P05-008	Application Number 10/040,430
	Applicant Crabtree et al.	
	Filing Date January 7, 2002	Group Art Unit 1656

CM	BJ	Rao, A. NF-AT: a transcription factor required for the co-ordinate induction of several cytokine genes. *Immunology Today* 15, 274-281 (1994).
	BK	Rao et al. U.S. Application No. 08/145,006, filed 5/11/93.
	BL	Rao et al. U.S. Application No. 08/017,052 filed 2/11/93.
	BM	Rao et al. U. S. Application No. 08/006,067 filed 1/15/93.
	BN	Riegel, J. et al. Nuclear Events after activation of CD4+8+ thymocytes. *J. Immunol.* 144, 6-3611-3618 (1990).
	BO	Shaw, J. et al. Identification of a putative regulator of early T cell activation genes. *Science* 241, 202-225 (1988).
	BP	Schmidt, A. et al. Inducible Nuclear Factor Binding to the kB elements of the human immunodeficiency virus enhancer in T cells can be blocked by cyclosporin A in a signal-dependent manner. *J. Virology* 64, 4037-4041 (1990).
	BQ	Schreiber, S. Chemistry and biology of the immunophilins and their immunosuppressive ligands. *Science* 251, 283-287 (1991).
CM	BR	Verweij, C. et al. Cell type specificity and activation requirements for NF-AT-1 (Nuclear Factor of Activated T-cells) transcriptional activity determined by a new method using transgenic mice to assay transcriptional activity of an individual nuclear factor. *J. Biol. Chem.* 265, 15788-15795 (15 September 1990).

EXAMINER	DATE CONSIDERED
Carla Myers	10-14-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERERCE